Redeye: Egetis - Licensing agreement opens the path to Japan
Redeye provides an additional comment on the recent news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto. We argue that Egetis now has a credible strategy in Japan in place and see the deal as a confirmation of the merits of focusing on partnerships in regions beyond the US and EU.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/